Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-week, Multicenter Study to Assess the Time Course of Response to Secukinumab on Joint Inflammation Using Power Doppler Ultrasonography in Patients With Active Psoriatic Arthritis

Next Previous
Trial Profile

A 52-week, Multicenter Study to Assess the Time Course of Response to Secukinumab on Joint Inflammation Using Power Doppler Ultrasonography in Patients With Active Psoriatic Arthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms ULTIMATE
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 15 Nov 2023 Results evaluating the responsiveness of US enthesitis to SEC over 52 weeks and the correlation with clinical response of enthesitis presented at the ACR Convergence 2023
    • 03 Jun 2023 Results of exploratory analysis from Phase 3B, assessing the performance of different reduced joint sets to predict response to secukinumab, compared with the 24 paired joints included in the validated GLOESS in patients with active psoriatic arthritis, presented at the 24th Annual Congress of the European League Against Rheumatism.
    • 14 Nov 2022 Results to evaluate how well various reduced joint sets predict response to Secukinumab, compared with the total number of joints included in the GLOESS, presented at the ACR Convergence 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top